Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Short term Debt (2016 - 2022)

Spero Therapeutics (SPRO) has disclosed Short term Debt for 5 consecutive years, with $141000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Short term Debt changed N/A year-over-year to $141000.0, compared with a TTM value of $141000.0 through Sep 2022, changed N/A, and an annual FY2018 reading of $223000.0, changed 0.0% over the prior year.
  • Short term Debt was $141000.0 for Q3 2022 at Spero Therapeutics, up from $115000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $995000.0 in Q1 2022 and bottomed at $115000.0 in Q2 2022.
  • Average Short term Debt over 3 years is $281200.0, with a median of $223000.0 recorded in 2018.
  • Peak annual rise in Short term Debt hit 2.76% in 2018, while the deepest fall reached 0.0% in 2018.
  • Year by year, Short term Debt stood at $223000.0 in 2018, then changed by 0.0% to $223000.0 in 2019, then crashed by 36.77% to $141000.0 in 2022.
  • Business Quant data shows Short term Debt for SPRO at $141000.0 in Q3 2022, $115000.0 in Q2 2022, and $995000.0 in Q1 2022.